Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, Jiang T, Broadwater G, Hyslop T, Hall A, Laine M, Phung L, Greene GL, Martin LA, Pancholi S, Dowsett M, Detre S, Marks JR, Crawford GE, Brown M, Norris JD, Chang CY, McDonnell DP.

Cell Rep. 2019 Oct 22;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032.

2.

CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.

Alfaqih MA, Nelson ER, Liu W, Safi R, Jasper JS, Macias E, Geradts J, Thompson JW, Dubois LG, Freeman MR, Chang CY, Chi JT, McDonnell DP, Freedland SJ.

Cancer Res. 2017 Apr 1;77(7):1662-1673. doi: 10.1158/0008-5472.CAN-16-2738. Epub 2017 Jan 27.

3.

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.

Alexander PB, Chen R, Gong C, Yuan L, Jasper JS, Ding Y, Markowitz GJ, Yang P, Xu X, McDonnell DP, Song E, Wang XF.

J Biol Chem. 2017 Jan 13;292(2):748-759. doi: 10.1074/jbc.M116.754960. Epub 2016 Nov 30.

4.

ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.

Park S, Chang CY, Safi R, Liu X, Baldi R, Jasper JS, Anderson GR, Liu T, Rathmell JC, Dewhirst MW, Wood KC, Locasale JW, McDonnell DP.

Cell Rep. 2016 Apr 12;15(2):323-35. doi: 10.1016/j.celrep.2016.03.026. Epub 2016 Mar 31.

5.

ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling.

Wang J, Rouse C, Jasper JS, Pendergast AM.

Sci Signal. 2016 Feb 2;9(413):ra12. doi: 10.1126/scisignal.aad3210.

6.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

7.

Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.

Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP.

Mol Cancer Res. 2014 Dec;12(12):1829-39. doi: 10.1158/1541-7786.MCR-14-0195. Epub 2014 Aug 6.

8.

27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.

Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP.

Science. 2013 Nov 29;342(6162):1094-8. doi: 10.1126/science.1241908.

9.

ELF3 is a repressor of androgen receptor action in prostate cancer cells.

Shatnawi A, Norris JD, Chaveroux C, Jasper JS, Sherk AB, McDonnell DP, Giguère V.

Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.

10.

Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners.

Pollock JA, Larrea MD, Jasper JS, McDonnell DP, McCafferty DG.

ACS Chem Biol. 2012 Jul 20;7(7):1221-31. doi: 10.1021/cb300108c. Epub 2012 May 10.

11.

The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.

Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, McDonnell DP.

Cancer Cell. 2011 Oct 18;20(4):500-10. doi: 10.1016/j.ccr.2011.08.023.

Supplemental Content

Loading ...
Support Center